Orchid Pharma Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Orchid Pharma Ltd filed with BSE on 01 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Orchid Pharma reported Q4 FY26 standalone revenue of approximately Rs 238 crore, broadly stable versus Rs 237 crore in Q4 FY25, while full-year FY26 revenue fell to Rs 811 crore from Rs 922 crore in FY25 amid industry-wide pricing pressure in Cephalosporins. Management said gross margins recovered in Q4 after inventory revaluation losses hurt earlier quarters, and discussed progress on the 7ACA project, Exblifep commercialization, Cefiderocol facility, and the pending merger with Dhanuka Laboratories. Management also outlined plans to build fill-finish and formulation capabilities to target the U.S. sterile Cephalosporin market.
Numbers mentioned
Standalone revenue from operations: approximately INR238 crores (Q4 FY26)
p. 3
“For Q4 financial year '26, our standalone revenue for operations stood at approximately INR238 crores, broadly stable on a year-on-year basis compared to approximately INR237 crores in Q4 of financial year '25.”
Manish Dhanuka, page 3 of the filed PDF · View the filing
EBITDA: approximately INR42.3 crores (Q4 FY26)
p. 3
“Our EBITDA for Q4 stood at approximately INR42.3 crores compared to approximately INR40 crores in Q4 of '25.”
Manish Dhanuka, page 3 of the filed PDF · View the filing
Standalone revenue from operations: INR811 crores (FY26)
p. 3
“For full financial year '26, standalone revenue from operations stood at INR811 crores compared to INR922 crores in financial year '25.”
Manish Dhanuka, page 3 of the filed PDF · View the filing
EBITDA: INR101 crores (FY26)
p. 3
“FY '26 EBITDA stood at INR101 crores compared to INR155 crores in financial year '25.”
Manish Dhanuka, page 3 of the filed PDF · View the filing
AMS platform EBITDA drag: approximately INR8 crores annually
p. 5
“The platform currently remains an EBITDA drag of approximately INR8 crores annually.”
Manish Dhanuka, page 5 of the filed PDF · View the filing
U.S. sterile Cephalosporin opportunity size: approximately $1.2 billion
p. 6
“This overall opportunity size is estimated at approximately $1.2 billion.”
Manish Dhanuka, page 6 of the filed PDF · View the filing
Dhanuka Laboratories revenue: INR450 crores (FY26)
p. 11
“Yes. The revenue numbers are INR450 crores, which was INR500 crores last year, so almost same 10% reduction.”
Manish Dhanuka, page 11 of the filed PDF · View the filing
Q2/Q3 gross margins: around 31%, 32% (Q2-Q3 FY26)
p. 9
“Our Q2, Q3 gross margins were around 31%, 32%.”
Mridul Dhanuka, page 9 of the filed PDF · View the filing
7ACA current price: around $61
p. 11
“Yes, around $61 is the current price.”
Mridul Dhanuka, page 11 of the filed PDF · View the filing
Patients treated with Enmetazobactam: about 30,000 patients (last 12 months)
p. 13
“So about 30,000 patients we would have treated in last year.”
Mridul Dhanuka, page 13 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
7ACA project commissioning — commissioning in Q1 CY2027 · Q1 calendar year 2027
stated firmly by Manish Dhanuka
p. 4
“We are still committed to the commissioning in the first quarter of calendar year 2027.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Cefiderocol facility commissioning and launch — launch in Q2 or Q3 CY2027 · end of this calendar year commissioning, Q2/Q3 CY2027 launch
stated conditionally by Manish Dhanuka
p. 5
“Subject to regulatory approvals and registrations, we expect product launch during Q2 or Q3 of calendar year 2027.”
Manish Dhanuka, page 5 of the filed PDF · View the filing
Merger EBITDA margin expansion — 1% to 2% EBITDA margin expansion
stated as an aspiration by Manish Dhanuka
p. 4
“As these synergies begin getting realized over time, we internally estimate that the merger itself can potentially contribute nearly 1% to 2% EBITDA margin expansion.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
U.S. sterile product launches — approximately five to six large sterile products · over the next few years
stated as an aspiration by Manish Dhanuka
p. 5
“Over the next few years, Orchid plans to launch approximately five to six large sterile products catering to nearly two-thirds of the U.S. Cephalosporin market opportunity.”
Manish Dhanuka, page 5 of the filed PDF · View the filing
Base business EBITDA margin — around 12% · FY27
stated as an aspiration by Manish Dhanuka
p. 8
“Yes, Sagar, we are targeting something around that.”
Manish Dhanuka, page 8 of the filed PDF · View the filing
Base business revenue growth — 10% to 15% · FY27
stated as an aspiration by Manish Dhanuka
p. 10
“So we hope we can continue between 10% to 15% again this year.”
Manish Dhanuka, page 10 of the filed PDF · View the filing
Enmetazobactam lifetime sales — $1 billion to $2 billion · life of the patent
stated as an aspiration by Mridul Dhanuka
p. 7
“We still maintain the lifetime sales would be between $1 billion to $2 billion overall during the life of the patent.”
Mridul Dhanuka, page 7 of the filed PDF · View the filing
Enmetazobactam peak sales timing — fourth or fifth year of launch
stated as an aspiration by Mridul Dhanuka
p. 7
“And the peak should be reaching fourth or fifth year of the launch, not three years.”
Mridul Dhanuka, page 7 of the filed PDF · View the filing
Enmetazobactam out-licensing deals signing — 50% of markets under discussion · within six months
stated conditionally by Mridul Dhanuka
p. 15
“I would love to do that. But if you have to assume something, I would say 50% will be signed in for sure.”
Mridul Dhanuka, page 15 of the filed PDF · View the filing
Downstream products additional EBITDA — 5% kind of additional EBITDA
stated as an aspiration by Mridul Dhanuka
p. 13
“We had guided earlier of 5% kind of additional EBITDA on the downstream products.”
Mridul Dhanuka, page 13 of the filed PDF · View the filing
Shionogi project plant commissioning — December 2026 · December 2026
stated firmly by Manish Dhanuka
p. 15
“Yes, the plant commissioning, as earlier also announced, is going to be December of '26.”
Manish Dhanuka, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said negotiations are ongoing at term-sheet stage in some countries but no definitive agreement has been signed.
Answered by Mridul Dhanuka
Asked by Sagar: Update on Enmetazobactam out-licensing deals and the Japanese customer, and why no firm contract has been signed yet.
p. 6
“So depending on where they are, these long-term agreements are taking more time to negotiate than we thought originally.”
Mridul Dhanuka, page 6 of the filed PDF · View the filing
Management revised the peak timing to the fourth or fifth year and reiterated a $1-2 billion lifetime sales estimate.
Answered by Mridul Dhanuka
Asked by Sagar: Whether the previously stated $200-250 million peak sales target for Enmetazobactam still holds.
p. 7
“We still maintain the lifetime sales would be between $1 billion to $2 billion overall during the life of the patent.”
Mridul Dhanuka, page 7 of the filed PDF · View the filing
Management said total capex is around Rs 50 crore, mostly for filing and development expenses as part of the Cefiderocol facility.
Answered by Mridul Dhanuka
Asked by Sagar: Capex details on the fill-finish facility for the U.S. market.
p. 8
“So the total capex we are estimating is around INR50 crores, which includes equipment and capability but one size.”
Mridul Dhanuka, page 8 of the filed PDF · View the filing
Management attributed the April price increase to war-related anxiety and rising input costs, and said passing on costs fully is uncertain.
Answered by Manish Dhanuka
Asked by Nikhil Upadhyay: Whether the recent price improvement in the base business is sustainable or transient.
p. 9
“So we are trying to review prices on almost a weekly basis, so that we can beat this challenge.”
Manish Dhanuka, page 9 of the filed PDF · View the filing
Management declined to give an exact number but said Q1 losses were the largest due to price crashes on high-cost inventory.
Answered by Manish Dhanuka
Asked by Nikhil Upadhyay: Quantification of the inventory valuation loss mentioned earlier.
p. 9
“So I would not be able to put a number, but we believe that the first quarter, the loss was the maximum because we were carrying inventory having planned for a good growth during the year and suddenly the prices crashed 15%, 20%.”
Manish Dhanuka, page 9 of the filed PDF · View the filing
Management said the split was roughly 30% regulated and 70% rest-of-world for the full year.
Answered by Manish Dhanuka
Asked by Loveleen Bagga: Mix between regulated and emerging markets for FY26 and FY25.
p. 10
“For this year, whole year, 30% is regulated and 70% is ROW.”
Manish Dhanuka, page 10 of the filed PDF · View the filing
Management clarified that 25% is existing consumption and the rest will be converted downstream and sold from the Chennai facility, with only 20-25% sold to third parties as 7ACA itself.
Answered by Mridul Dhanuka
Asked by Vishal Manchanda: Clarification on the 75% in-house usage figure for 7ACA versus earlier 25% guidance.
p. 12
“So if you look at only 7ACA basis, only 20%, 25% would be sold to third-parties.”
Mridul Dhanuka, page 12 of the filed PDF · View the filing
Management said the downstream capex would have a very high asset turn and reiterated an earlier guidance of additional EBITDA contribution.
Answered by Mridul Dhanuka
Asked by Vishal Manchanda: How the downstream products will affect margins and asset turns.
p. 13
“So for the downstream only capex addition, the asset turn would be very, very high because it's intermediate and it does not require the same level of clean room and investment.”
Mridul Dhanuka, page 13 of the filed PDF · View the filing
Management said it expects about 50% to be signed given the lengthy due diligence process.
Answered by Mridul Dhanuka
Asked by Rupesh Tatiya: Whether all Enmetazobactam out-licensing deals across discussed geographies will be finalized within six months.
p. 15
“Because it takes a long time. We've acquired this six months ago, the discussion on out-licensing, a lot of due diligence going on and then they want to take the patents, all of that takes time.”
Mridul Dhanuka, page 15 of the filed PDF · View the filing
Risks flagged
Global pricing and volume pressure in the antibiotic industry
p. 3
“Financially, it has been a challenging year for the global antibiotic industry with significant pricing and volume pressure across several products and geographies.”
Manish Dhanuka, page 3 of the filed PDF · View the filing
Inventory valuation losses from price erosion
p. 4
“During the last three quarters, the price erosion, combined with the downward valuation of inventories led to lesser gross margins.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Ongoing uncertainty from war, supply chain costs, and geopolitical situation affecting pricing
p. 4
“Going forward, we still need to monitor the impact of pricing due to the war, supply chain costs, global competitive intensity and geopolitical situations.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Competitive pricing pressure in non-regulated markets due to capacity additions
p. 8
“So we do understand that the pricing in the non-regulated markets will be competitive, and we have to continue to make ourselves more competitive all the time.”
Manish Dhanuka, page 8 of the filed PDF · View the filing
Uncertainty in passing on rising input costs to customers
p. 9
“Now it remains to be seen whether we will be able to pass on all the costs that are increasing or only partly.”
Manish Dhanuka, page 9 of the filed PDF · View the filing
Difficulty identifying the right molecule and market in synthetic APIs amid Chinese competition
p. 14
“But you understand it's not that easy in today's environment with China creating huge capacity.”
Manish Dhanuka, page 14 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.